DBV Technologies S.A. (EPA:DBV)

Market Cap	1.00B +358.4%
Revenue (ttm)	4.97M +61.9%
Net Income	-145.23M
EPS	-0.66
Shares Out	295.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	553,697
Average Volume	870,586
Open	3.430
Previous Close	3.380
Day's Range	3.342 - 3.510
52-Week Range	1.304 - 4.500
Beta	-0.24
RSI	46.25
Earnings Date	Apr 30, 2026

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 161
• Stock Exchange: Euronext Paris
• Ticker Symbol: DBV

Financial Performance

In 2025, DBV Technologies's revenue was $5.64 million, an increase of 35.77% compared to the previous year's $4.15 million. Losses were -$146.95 million, 29.0% more than in 2024.

Financial numbers in USD